In February 2014, Dilafor entered into licensing and partnership agreement with Lee´s Pharmaceuticals.  According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan.

http://dilafor.com/upl/files/136614/dilafor-enters-into-a-license-and-partnership-agreement-with-lee-s-pharmaceutical.pdf


In August 2014, Dilafor entered into a commercial manufacturing and partnership agreement with Opocrin S.p.A for the manufacturing of the active ingredient tafoxiparin. Opocrin is appointed as the main commercial manufacturing partner for Dilafor’s candidate drug for the European, US, CIS and Japanese markets.

http://dilafor.com/upl/files/136609/pr-opocrin-dilafor-final-2014-10-07.pdf

“I am delighted that my 40 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address protracted labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO at start of phase IIb